Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLG) Research & Development (2016 - 2017)

Bone Biologics (BBLG) has disclosed Research & Development for 2 consecutive years, with $350405.0 as the latest value for Q4 2017.

  • On a quarterly basis, Research & Development fell 49.76% to $350405.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $1.4 million, a 86.08% decrease, with the full-year FY2025 number at $1.1 million, down 50.23% from a year prior.
  • Research & Development was $350405.0 for Q4 2017 at Bone Biologics, up from $234264.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $4.7 million in Q1 2016 to a low of $234264.0 in Q3 2017.